A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma

Abstract Background The patient population with stage III non-small-cell lung cancer (NSCLC) is heterogeneous, with varying staging characteristics and diverse treatment options. Despite the potential practice-changing implications of randomized controlled trials evaluating the efficacy of periopera...

Full description

Bibliographic Details
Main Authors: Chieh-Lung Chen, Sing-Ting Wang, Wei-Chih Liao, Chia-Hung Chen, Chih-Yen Tu, Te-Chun Hsia, Wen-Chien Cheng, Hung-Jen Chen
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Cancer
Subjects:
Adenocarcinoma
Chemotherapy
Epidermal growth factor receptor (EGFR)
Stage III
Surgery
Tyrosine kinase inhibitor (TKI)
Online Access:https://doi.org/10.1186/s12885-023-11342-y

Internet

https://doi.org/10.1186/s12885-023-11342-y

Similar Items